Taslimi Y, Zahedifard F, Rafati S
Department of Immunotherapy and Leishmania Vaccine Research,Pasteur Institute of Iran,Tehran,Iran.
Parasitology. 2018 Apr;145(4):497-507. doi: 10.1017/S003118201600216X. Epub 2016 Dec 15.
Leishmaniasis is a vector-borne infectious disease caused by multiple Leishmania (L.) species with diverse clinical manifestations. There is currently no vaccine against any form of the disease approved in humans, and chemotherapy is the sole approach for treatment. Unfortunately, treatment options are limited to a small number of drugs, partly due to high cost and significant adverse effects. The other obstacle in leishmaniasis treatment is the potential for drug resistance, which has been observed in multiple endemic countries. Immunotherapy maybe another important avenue for controlling leishmaniasis and could help patients control the disease. There are different approaches for immunotherapy in different infectious diseases, generally with low-cost, limited side-effects and no possibility to developing resistance. In this paper, different immunotherapy approaches as alternatives to routine drug treatment will be reviewed against leishmaniasis.
利什曼病是一种由多种利什曼原虫引起的媒介传播传染病,具有多种临床表现。目前尚无针对任何形式的该疾病的人类批准疫苗,化疗是唯一的治疗方法。不幸的是,治疗选择仅限于少数几种药物,部分原因是成本高昂且副作用严重。利什曼病治疗中的另一个障碍是耐药性的可能性,这在多个流行国家都有观察到。免疫疗法可能是控制利什曼病的另一条重要途径,并有助于患者控制疾病。不同传染病的免疫疗法有不同的方法,通常成本低、副作用有限且不存在产生耐药性的可能性。本文将综述针对利什曼病的不同免疫疗法作为常规药物治疗替代方案的情况。